AI-Powered Drug Discovery Hits Major Milestone with First Fully AI-Designed Cancer Therapy Entering Phase 2 Trials
Insilico Medicine announced that its first completely AI-generated small-molecule drug for a rare form of lung cancer has advanced to Phase 2 clinical trials. The compound was designed, synthesized, and optimized entirely by the company’s generative AI platform in under 18 months — a process that traditionally takes 5–7 years.
